Exopulse Mollii Suit, Motor Functions & CP Children With Cerebral Palsy
NCT: NCT05885139 · COMPLETED
Brief Summary
Cerebral Palsy (CP) is is estimated to be around 1.5-3 per live birth, with prenatal factors accounting for 75% of cases. CP appears in early childhood and persists with age and is characterized by permanent lesions or abnormalities affecting the immature brain. It mainly occurs as a motor system disorder (e.g., abnormal movements or posture) with the presence of hemiplegia, diplegia or tetraplegia, and spastic, dyskinetic or atactic syndromes. .This study will explore the potential clinical benefits of the Molliimethod in children with cerebral palsy. Spasticity impacts balance and mobility, halts the patients quality of life and their ability to perform their activity of daily living, and could also increase the risk of fractures and falls. Available interventions that aim on improving spasticity are facing limitations such as varios side effects. Therefore, developing novel therapies such as the EXOPULSE Mollii Suit could help to overcome such limitations and noninvasively improve balance, mobility, quality of life and reduce spasticity and pain in children with CP.
Frequently Asked Questions
What is Exopulse Mollii Suit, Motor Functions & CP Children With Cerebral Palsy?
Exopulse Mollii Suit, Motor Functions & CP Children With Cerebral Palsy is a clinical trial registered under NCT05885139. Current status: COMPLETED.
What is the status of NCT05885139?
The current status of NCT05885139 (Exopulse Mollii Suit, Motor Functions & CP Children With Cerebral Palsy) is: COMPLETED.
When did Exopulse Mollii Suit, Motor Functions & CP Children With Cerebral Palsy start?
Exopulse Mollii Suit, Motor Functions & CP Children With Cerebral Palsy started on 2023-04-17.
Official Source
View on ClinicalTrials.gov →Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.